Ming Yan - 18 May 2023 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
Chief Technology Officer, Director
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Ming Yan
Issuer symbol
CTKB
Transactions as of
18 May 2023
Net transactions value
-$161,756
Form type
4
Filing time
19 May 2023, 20:09:47 UTC
Previous filing
20 Apr 2023
Next filing
21 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTKB Common Stock Options Exercise +1,981 +0.03% 7,888,034 18 May 2023 Direct F1
transaction CTKB Common Stock Tax liability $5,165 -772 -0.01% $6.69 7,887,262 18 May 2023 Direct F2
transaction CTKB Common Stock Options Exercise +4,908 +0.06% 7,892,170 18 May 2023 Direct F1
transaction CTKB Common Stock Tax liability $12,791 -1,912 -0.02% $6.69 7,890,258 18 May 2023 Direct F2
transaction CTKB Common Stock Sale $143,800 -20,000 -0.25% $7.19 7,870,258 19 May 2023 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTKB Restricted Stock Units Options Exercise $0 -1,981 -8.6% $0.000000 21,142 18 May 2023 Common Stock 1,981 Direct F1, F5
transaction CTKB Restricted Stock Units Options Exercise $0 -4,908 -4.2% $0.000000 112,905 18 May 2023 Common Stock 4,908 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2 Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.96 to $7.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.
F6 The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested.